IBD in the time of corona - vigilance for immune-mediated diseases

Alexander R Moschen, Alexander R Moschen

Abstract

The gastrointestinal tract represents a target organ for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), warranting a thorough discussion on the consequences, particularly regarding inflammatory bowel diseases. Here, aspects of gastrointestinal involvement with SARS-CoV-2, the role of viruses as modulators of mucosal immunity and as treatment-related safety hazards, and the current clinical evidence will be discussed.

Trial registration: ClinicalTrials.gov NCT04276688 NCT04354259.

Conflict of interest statement

The author declares no competing interests.

References

    1. Neurath MF. Covid-19 and immunomodulation in IBD. Gut. 2020 doi: 10.1136/gutjnl-2020-321269.
    1. Lamers MM, et al. SARS-CoV-2 productively infects human gut enterocytes. Science. 2020 doi: 10.1126/science.abc1669.
    1. Cadwell K, et al. Virus-plus-susceptibility gene interaction determines Crohn’s disease gene Atg16L1 phenotypes in intestine. Cell. 2010;141:1135–1145. doi: 10.1016/j.cell.2010.05.009.
    1. Bouziat R, et al. Reovirus infection triggers inflammatory responses to dietary antigens and development of celiac disease. Science. 2017;356:44–50. doi: 10.1126/science.aah5298.
    1. Verdoni L, et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. Lancet. 2020 doi: 10.1016/S0140-6736(20)31103-X.
    1. Jostins L, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012;491:119–124. doi: 10.1038/nature11582.
    1. Tilg H, Moschen AR, Kaser A. Suppression of interleukin-17 by type I interferons: a contributing factor in virus-induced immunosuppression? Eur. Cytokine Netw. 2009;20:1–6. doi: 10.1684/ecn.2009.0141.
    1. Ali T, Yun L, Shapiro D, Madhoun MF, Bronze M. Viral infections in patients with inflammatory bowel disease on immunosuppressants. Am. J. Med. Sci. 2012;343:227–232. doi: 10.1097/MAJ.0b013e31821ff728.
    1. Bezzio C, et al. Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study. Gut. 2020 doi: 10.1136/gutjnl-2020-321411.
    1. Brenner, E. J. et al. Corticosteroids, but not TNF antagonists, are associated with adverse COVID-19 outcomes in patients with inflammatory bowel diseases: results from an international registry. Gastroenterology10.1053/j.gastro.2020.05.032 (in press).

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere